Phase 3 data support a lower age threshold for linaclotide, making it the first prescription therapy approved for functional constipation in patients ages 2 to 5.

The FDA expanded its approval of linaclotide to include pediatric patients aged 2 to 5 years with functional ...

Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...

Ironwood Pharmaceuticals (IRWD) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie (ABBV)-partnered bowel disorder therapy Linzess to treat children ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with irritable bowel syndrome with constipation (IBS-C), as the former ...

– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced today ...

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

Ironwood Pharmaceuticals is rated Hold, with the current market price reflecting a discount and potential for upside. Learn ...